• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Cutera Inc.

    3/5/25 5:17:52 PM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CUTR alert in real time by email
    S-8 POS 1 cutr-sx8posams.htm S-8 POS Document

    As filed with the Securities and Exchange Commission on March 5, 2025
    Registration No. 333-114149
    Registration No. 333-123495
    Registration No. 333-132583
    Registration No. 333-141376
    Registration No. 333-149703
    Registration No. 333-158160
    Registration No. 333-187502
    Registration No. 333-206864
    Registration No. 333-221542
    Registration No. 333-258283
    Registration No. 333-271214
    Registration No. 333-273924
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 114149 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 123495 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 132583 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 141376 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 149703 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 158160 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 187502 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 206864 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 221542 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 258283 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 271214 
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333- 273924 
    UNDER THE SECURITIES ACT OF 1933
     
    CUTERA, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware 77-0492262
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification No.)
    3240 Bayshore Blvd.
    Brisbane, California 94005
    (Address of principal executive offices, including zip code)

    1998 Stock Plan



    2004 Equity Incentive Plan
    2004 Employee Stock Purchase Plan
    2019 Equity Incentive Plan
    2023 Inducement Equity Incentive Plan
    (Full title of the plans)

    Taylor Harris
    Chief Executive Officer
    Cutera, Inc.
    3240 Bayshore Blvd.
    Brisbane, California 94005
    (415) 657-5500
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
     
    With copies to:

    Marianne Sarrazin
    Goodwin Procter LLP
    525 Market Street, 32nd Floor
    San Francisco, CA 94105
    (415) 733-6000
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☐
      Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
     
     



    DEREGISTRATION OF SECURITIES
    This Post-Effective Amendment relates to the following Registration Statements of Cutera, Inc., a Delaware corporation (the “Registrant”), on Form S-8 (collectively, the “Registration Statements”), which have been previously filed with the Securities and Exchange Commission (the “SEC”), to deregister any and all shares of the Registrant’s common stock, par value $0.001 per share (the “Registrant’s Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:
     
    • Registration Statement No. 333-114149, filed with the SEC on April 2, 2004, registering a total of 3,833,917 shares of the Registrant’s Common Stock issuable upon exercise of then presently outstanding options issued under the Registrant’s 1998 Stock Plan, a total of 1,889,404 shares of the Registrant’s Common Stock issuable upon exercise of options that had not yet been granted under the Registrant’s 1998 Stock Plan and shares to be granted under the Registrant’s 2004 Equity Incentive Plan, and a total of 200,000 shares of the Registrant’s Common Stock under the Registrant’s 2004 Employee Stock Purchase Plan;

    • Registration Statement No. 333-123495, filed with the SEC on March 22, 2005, registering a total of 547,860 shares of the Registrant’s Common Stock under the Registrant’s 2004 Equity Incentive Plan and a total of 219,144 shares of the Registrant’s Common Stock under the Registrant’s 2004 Employee Stock Purchase Plan;

    • Registration Statement No. 333-132583, filed with the SEC on March 20, 2006, registering a total of 610,674 shares of the Registrant’s Common Stock under the Registrant’s 2004 Equity Incentive Plan and a total of 244,269 shares of the Registrant’s Common Stock under the Registrant’s 2004 Employee Stock Purchase Plan;

    • Registration Statement No. 333-141376, filed with the SEC on March 16, 2007, registering a total of 646,969 shares of the Registrant’s Common Stock under the Registrant’s 2004 Equity Incentive Plan and a total of 258,788 shares of the Registrant’s Common Stock under the Registrant’s 2004 Employee Stock Purchase Plan;

    • Registration Statement No. 333-149703, filed with the SEC on March 13, 2008, registering a total of 636,922 shares of the Registrant’s Common Stock under the Registrant’s 2004 Equity Incentive Plan and a total of 254,769 shares of the Registrant’s Common Stock under the Registrant’s 2004 Employee Stock Purchase Plan;

    • Registration Statement No. 333-158160, filed with the SEC on March 24, 2009, registering a total of 256,121 shares of the Registrant’s Common Stock under the Registrant’s 2004 Employee Stock Purchase Plan;

    • Registration Statement No. 333-187502, filed with the SEC on March 25, 2013, registering a total of 1,910,000 shares of the Registrant’s Common Stock under the Registrant’s 2004 Equity Incentive Plan;

    • Registration Statement No. 333-206864, filed with the SEC on September 10, 2015, registering a total of 1,500,000 shares of the Registrant’s Common Stock under the Registrant’s 2004 Equity Incentive Plan;

    • Registration Statement No. 333-221542, filed with the SEC on November 14, 2017, registering a total of 1,600,000 shares of the Registrant’s Common Stock under the Registrant’s Amended and Restated 2004 Equity Incentive Plan;

    • Registration Statement No. 333-258283, filed with the SEC on July 30, 2021, registering a total of 1,750,000 shares of the Registrant’s Common Stock under the Registrant’s Amended and Restated 2019 Equity Incentive Plan;

    • Registration Statement No. 333-271214, filed with the SEC on April 11, 2023, registering a total of 600,000 shares of the Registrant’s Common Stock under the Registrant’s Amended and Restated 2019 Equity Incentive Plan; and

    • Registration Statement No. 333- 273924, filed with the SEC on August 11, 2023, registering a total of 1,300,000 shares of the Registrant’s Common Stock under the Registrant’s Amended and Restated 2019 Equity Incentive Plan and a total of 2,500,000 shares of the Registrant’s Common Stock under the Registrant’s 2023 Inducement Equity Incentive Plan.
     

     

     

     




    As previously disclosed, on March 5, 2025, the Registrant and certain of its subsidiaries commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. In connection with the foregoing, the offerings pursuant to the Registration Statements are being terminated.
    In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offering, the Registrant hereby removes from registration all securities that were registered but unsold or otherwise unissued under each of the Registration Statements as of the date hereof.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the Brisbane, State of California, on this 5th day of March, 2025.
     
    CUTERA, INC.


    By:    /s/ Stuart Drummond    
    Name:     Stuart Drummond
    Title:    Interim Chief Financial Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $CUTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CUTR

    DatePrice TargetRatingAnalyst
    3/22/2024Underperform → Mkt Perform
    William Blair
    7/27/2023$14.00 → $18.00Underweight → Neutral
    Piper Sandler
    5/11/2023Outperform → Mkt Perform
    William Blair
    5/10/2023$14.00Underweight
    Piper Sandler
    3/30/2023Buy → Hold
    Maxim Group
    1/31/2023Mkt Perform
    William Blair
    1/11/2023$85.00 → $33.00Overweight → Neutral
    Cantor Fitzgerald
    12/28/2022$78.00 → $68.00Overweight
    Stephens
    More analyst ratings

    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cutera Inc.

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      11/12/24 2:37:12 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cutera Inc.

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      11/4/24 11:30:30 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cutera Inc.

      SC 13D/A - CUTERA INC (0001162461) (Subject)

      9/3/24 4:14:32 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cutera upgraded by William Blair

      William Blair upgraded Cutera from Underperform to Mkt Perform

      3/22/24 7:28:54 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously

      7/27/23 11:27:23 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera downgraded by William Blair

      William Blair downgraded Cutera from Outperform to Mkt Perform

      5/11/23 7:25:52 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Cutera® Appoints Jeryl L. Hilleman to Board of Directors

      Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar

      6/10/24 4:30:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Appoints Stephana Patton as Chief Legal Officer

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

      11/13/23 8:30:00 AM ET
      $CUTR
      $EIGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cutera, Inc. Appoints Brent Hauser as President, International

      Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest

      10/2/23 8:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cutera Inc.

      EFFECT - CUTERA INC (0001162461) (Filer)

      3/26/25 12:15:06 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form POS AM filed by Cutera Inc.

      POS AM - CUTERA INC (0001162461) (Filer)

      3/25/25 6:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Cutera Inc.

      25 - CUTERA INC (0001162461) (Filer)

      3/20/25 12:48:01 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cutera® Successfully Completes Restructuring Transaction and Moves Forward with Enhanced Capital Structure

      Emerges from Chapter 11 as a stronger company, well positioned for long-term growth Continuing to provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11. Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from its existing lenders. "Today marks a significant mile

      5/1/25 5:20:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Announces Voluntarily Delisting from Nasdaq

      Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The s

      3/10/25 3:41:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Takes Steps to Strengthen Financial Foundation and Position the Company for Long-Term Success

      Enters into agreement to reduce debt by nearly $400 million and raise $65 million of new money from existing lenders Implementing pre-packaged financial restructuring plan with strong support of lenders, expected to emerge expeditiously within 60 days Continues to operate as usual and provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term s

      3/5/25 7:10:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Patton Stephana Eilene covered exercise/tax liability with 623 shares, decreasing direct ownership by 0.80% to 77,216 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:43:37 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Harris Taylor C. covered exercise/tax liability with 4,620 shares, decreasing direct ownership by 2% to 255,744 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:42:45 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Wierbicki Paul

      3 - CUTERA INC (0001162461) (Issuer)

      2/19/25 4:04:44 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Financials

    Live finance-specific insights

    See more
    • Cutera® Announces Third Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to

      11/7/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® to Announce Third Quarter Results on November 7, 2024

      Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai

      10/7/24 6:48:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Second Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al

      8/8/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care